SCHEMBL6320268

SCHEMBL6320268

CN(C)CC(=O)NCc1ccc(NC(=C2C(=O)Nc3ccccc32)c2ccccc2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.40
NAMPT P43490 3/20 0.39
ALDH1A1 P00352 1/20 0.39
GLA P06280 1/20 0.39
GAA P10253 1/20 0.39
CASP3 P42574 1/20 0.38
NPC1 O15118 3/20 0.38
RAB9A P51151 3/20 0.38
IDO1 P14902 2/20 0.38
TDO2 P48775 1/20 0.38
MAPT P10636 1/20 0.38
MEN1 O00255 1/20 0.37
TP53 P04637 1/20 0.37
HPGD P15428 1/20 0.37
KMT2A Q03164 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
KDR P35968 1/20 0.37
LSS P48449 1/20 0.36
AKT2 P31751 2/20 0.36
ALOX15 P16050 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6319510 1.00 PTPN1 (0.40) PTPN1NAMPTALDH1A1GLAGAA
SCHEMBL6319713 0.90 IDO1 (0.42) ALDH1A1IDO1TDO2MAPTKDR
SCHEMBL6319706 0.90 IDO1 (0.42) ALDH1A1IDO1TDO2MAPTKDR
SCHEMBL6328124 0.87 PTPN1 (0.49) PTPN1NAMPTALDH1A1NPC1RAB9A
SCHEMBL6328129 0.87 PTPN1 (0.49) PTPN1NAMPTALDH1A1NPC1RAB9A
SCHEMBL6324724 0.86 L3MBTL1 (0.42) PTPN1NAMPTALDH1A1CASP3NPC1
SCHEMBL6324728 0.86 L3MBTL1 (0.42) PTPN1NAMPTALDH1A1CASP3NPC1
SCHEMBL6318500 0.86 EGFR (0.41) ALDH1A1GAACASP3NPC1RAB9A
SCHEMBL6318492 0.86 EGFR (0.41) ALDH1A1GAACASP3NPC1RAB9A
Hydrochloric Acid SCHEMBL6327307 0.86 AKT2 (0.45) PTPN1NAMPTCASP3NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6855710-B2 Substituted indolines with an inhibitory effect on various kinases and complexes of CDKs BOEHRINGER INGELHEIM PHARMA KG (DE) 2005-02-15 US disclosed
US-20040058978-A1 Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-03-25 US disclosed
EP-1115704-B1 NOVEL SUBSTITUTED INDOLINONES WITH AN INHIBITORY EFFECT ON VARIOUS KINASES AND CYCLIN/CDK COMPLEXES BOEHRINGER INGELHEIM PHARMA (DE) 2003-06-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058978-A1 Novel substituted indolines with an inhibitory effect on various kinases and complexes of CDKs CDK1, CDK2, CDK3 PTPN1 429/4885NAMPT 2246/4885ALDH1A1 1810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.